LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 53

Search options

  1. Article ; Online: The Cardiovascular Complications of Chimeric Antigen Receptor T Cell Therapy.

    Jamal, Faizi A / Khaled, Samer K

    Current hematologic malignancy reports

    2020  Volume 15, Issue 2, Page(s) 130–132

    Abstract: Purpose of review: Chimeric antigen receptor T cell therapy is gaining clinical use in the management of B cell lymphomas. As the use of this unique treatment option increases, its associated toxicities will require recognition and treatment. In this ... ...

    Abstract Purpose of review: Chimeric antigen receptor T cell therapy is gaining clinical use in the management of B cell lymphomas. As the use of this unique treatment option increases, its associated toxicities will require recognition and treatment. In this review, we aim to discuss the cardiovascular toxicities of chimeric antigen receptor T cell therapy and our approach to their clinical management.
    Recent findings: Cardiotoxicity may be due to direct or indirect effects of infused chimeric antigen receptor T cells. The cytokine release syndrome has been described extensively in the literature. Studies have also reported cardiovascular dysfunction including hypotension, left ventricular dysfunction, heart failure, and cardiogenic shock in the setting of cytokine release syndrome. While there are no standardized guidelines for the treatment of cytokine release syndrome or associated cardiotoxicity, we present our current clinical practices. Further research is indicated into the pathophysiology of therapy-associated cardiac dysfunction and effective management strategies to optimize patient outcomes.
    MeSH term(s) Animals ; Cardiotoxicity ; Cardiovascular Diseases/etiology ; Cardiovascular Diseases/immunology ; Cardiovascular Diseases/physiopathology ; Cardiovascular Diseases/prevention & control ; Cardiovascular System/immunology ; Cardiovascular System/physiopathology ; Cytokine Release Syndrome/etiology ; Cytokine Release Syndrome/immunology ; Cytokine Release Syndrome/physiopathology ; Cytokine Release Syndrome/prevention & control ; Hematologic Neoplasms/immunology ; Hematologic Neoplasms/therapy ; Humans ; Immunotherapy, Adoptive/adverse effects ; Prognosis ; Receptors, Chimeric Antigen/immunology ; Risk Assessment ; Risk Factors ; T-Lymphocytes/immunology ; T-Lymphocytes/transplantation
    Chemical Substances Receptors, Chimeric Antigen
    Language English
    Publishing date 2020-03-12
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2229765-0
    ISSN 1558-822X ; 1558-8211
    ISSN (online) 1558-822X
    ISSN 1558-8211
    DOI 10.1007/s11899-020-00567-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6332: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Current Management and New Developments in the Treatment of Myelodysplastic Syndrome.

    Arslan, Shukaib / Khaled, Samer / Nakamura, Ryotaro

    Cancer treatment and research

    2021  Volume 181, Page(s) 115–132

    Abstract: Myelodysplastic syndrome (MDS) is a heterogeneous hematological neoplasm with a wide range of clinical presentations from isolated anemia to pancytopenia and propensity to transform to acute myeloid leukemia. MDS is characterized by morphologic bone ... ...

    Abstract Myelodysplastic syndrome (MDS) is a heterogeneous hematological neoplasm with a wide range of clinical presentations from isolated anemia to pancytopenia and propensity to transform to acute myeloid leukemia. MDS is characterized by morphologic bone marrow dysplasia and ineffective hematopoiesis resulting from a range of cytogenetic abnormalities and somatic gene mutations. Disease management varies from observation alone for low-risk disease to hypomethylating agents and hematopoietic cell transplantation (HCT) for higher risk disease. In this chapter, we review the classification, risk stratification, and optimal management of patients with MDS.
    MeSH term(s) Chromosome Aberrations ; Hematopoietic Stem Cell Transplantation ; Humans ; Leukemia, Myeloid, Acute ; Myelodysplastic Syndromes/therapy
    Language English
    Publishing date 2021-10-09
    Publishing country United States
    Document type Journal Article ; Review
    ISSN 0927-3042
    ISSN 0927-3042
    DOI 10.1007/978-3-030-78311-2_7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Cytokine Release Syndrome With the Novel Treatments of Acute Lymphoblastic Leukemia: Pathophysiology, Prevention, and Treatment.

    Aldoss, Ibrahim / Khaled, Samer K / Budde, Elizabeth / Stein, Anthony S

    Current oncology reports

    2019  Volume 21, Issue 1, Page(s) 4

    Abstract: Purpose of review: T cell-based therapies (blinatumomab and CAR T cell therapy) have produced unprecedented responses in relapsed and refractory (r/r) acute lymphoblastic leukemia (ALL) but is accompanied with significant toxicities, of which one of the ...

    Abstract Purpose of review: T cell-based therapies (blinatumomab and CAR T cell therapy) have produced unprecedented responses in relapsed and refractory (r/r) acute lymphoblastic leukemia (ALL) but is accompanied with significant toxicities, of which one of the most common and serious is cytokine release syndrome (CRS). Here we will review the pathophysiology, prevention, and treatment of CRS.
    Recent findings: Efforts have been initiated to define and grade cytokine release syndrome (CRS), to identify patients at risk, to describe biomarkers that predict onset and severity, to understand the pathophysiology, and to prevent and treat severe cases to reduce T cell immunotherapy-related morbidity and mortality. Optimizing the timing of T cell-based therapies in ALL, identifying new biomarkers, and investigating novel anti-cytokine agents that have anti-CRS activity are likely to be fruitful avenues of study.
    MeSH term(s) Cytokine Release Syndrome/etiology ; Cytokine Release Syndrome/physiopathology ; Cytokine Release Syndrome/therapy ; Cytokines/metabolism ; Humans ; Immunotherapy/adverse effects ; Immunotherapy, Adoptive/adverse effects ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy
    Chemical Substances Cytokines
    Language English
    Publishing date 2019-01-21
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2057359-5
    ISSN 1534-6269 ; 1523-3790
    ISSN (online) 1534-6269
    ISSN 1523-3790
    DOI 10.1007/s11912-019-0753-y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5521: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Correction: TET2 deficiency promotes MDS-associated leukemogenesis.

    Huang, Feiteng / Sun, Jie / Chen, Wei / Zhang, Lei / He, Xin / Dong, Haojie / Wu, Yuhui / Wang, Hanying / Li, Zheng / Ball, Brian / Khaled, Samer / Marcucci, Guido / Li, Ling

    Blood cancer journal

    2023  Volume 13, Issue 1, Page(s) 174

    Language English
    Publishing date 2023-11-28
    Publishing country United States
    Document type Published Erratum
    ZDB-ID 2600560-8
    ISSN 2044-5385 ; 2044-5385
    ISSN (online) 2044-5385
    ISSN 2044-5385
    DOI 10.1038/s41408-023-00952-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Donor-derived CD19-targeted chimeric antigen receptor T cells in adult transplant recipients with relapsed/refractory acute lymphoblastic leukemia.

    Aldoss, Ibrahim / Khaled, Samer K / Wang, Yan / Wang, Xiuli / Palmer, Joycelynne / Clark, Mary C / Wagner, Jamie R / Paul, Jinny / Vyas, Vibhuti / Brown, Christine E / Forman, Stephen J

    Blood cancer journal

    2023  Volume 13, Issue 1, Page(s) 107

    MeSH term(s) Humans ; Adult ; Receptors, Chimeric Antigen/genetics ; Transplant Recipients ; Tissue Donors ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy ; T-Lymphocytes
    Chemical Substances Receptors, Chimeric Antigen
    Language English
    Publishing date 2023-07-12
    Publishing country United States
    Document type Letter ; Research Support, N.I.H., Extramural
    ZDB-ID 2600560-8
    ISSN 2044-5385 ; 2044-5385
    ISSN (online) 2044-5385
    ISSN 2044-5385
    DOI 10.1038/s41408-023-00881-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Identifying signs and symptoms of AL amyloidosis in electronic health records using natural language processing, diagnosis codes, and manually abstracted registry data.

    Silvert, Eli / Hester, Laura / Ramudu, Eshwan / Pawlowski, Colin / Kranenburg, Britte / Buadi, Francis / Muchtar, Eli / Khaled, Samer / Tran, Namphuong / Soundararajan, Venky / Khan, Najat / Gertz, Morie / Dispenzieri, Angela

    American journal of hematology

    2023  Volume 98, Issue 9, Page(s) E255–E258

    MeSH term(s) Humans ; Electronic Health Records ; Natural Language Processing ; Immunoglobulin Light-chain Amyloidosis/diagnosis ; Routinely Collected Health Data ; Algorithms
    Language English
    Publishing date 2023-07-04
    Publishing country United States
    Document type Letter ; Research Support, Non-U.S. Gov't
    ZDB-ID 196767-8
    ISSN 1096-8652 ; 0361-8609
    ISSN (online) 1096-8652
    ISSN 0361-8609
    DOI 10.1002/ajh.27019
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1251: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: Totally implantable venous access system (TIVAS) Complicated by Tracheo-Venous Fistula.

    Khaled, Samer / Gotlieb, Vladimir / Patel, Arunbai

    Radiology case reports

    2016  Volume 4, Issue 1, Page(s) 266

    Abstract: Totally implantable venous access system (TIVAS) are widely used for various indications including chemotherapy infusion. The use of TIVAS is associated with number of complications that can occur as early as the time of insertion or can take place ... ...

    Abstract Totally implantable venous access system (TIVAS) are widely used for various indications including chemotherapy infusion. The use of TIVAS is associated with number of complications that can occur as early as the time of insertion or can take place months later. We report a case of a 64 year old female with recurrent osteosarcoma of the mandible. She had a port-a-catheter placed for chemotherapy infusion. The patient developed fistula between the Innominate Vein and the trachea, which found to be secondary to a spontaneous migration of the tip of the catheter. To our knowledge this is the first case of this kind to be reported. This complication, although very rare, can be life threatening, and should be considered when there is a malfunction of the TIVAS.
    Language English
    Publishing date 2016-10-04
    Publishing country Netherlands
    Document type Case Reports
    ZDB-ID 2406300-9
    ISSN 1930-0433
    ISSN 1930-0433
    DOI 10.2484/rcr.v4i1.266
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article: Acute Myeloid Leukemia: Biologic, Prognostic, and Therapeutic Insights.

    Khaled, Samer / Al Malki, Monzr / Marcucci, Guido

    Oncology (Williston Park, N.Y.)

    2016  Volume 30, Issue 4, Page(s) 318–329

    Abstract: Acute myeloid leukemia (AML) is a biologically complex and molecularly and clinically heterogeneous disease, and its incidence is increasing as the population ages. Unfortunately, currently used "one-size-fits-all" chemotherapy regimens result in cure ... ...

    Abstract Acute myeloid leukemia (AML) is a biologically complex and molecularly and clinically heterogeneous disease, and its incidence is increasing as the population ages. Unfortunately, currently used "one-size-fits-all" chemotherapy regimens result in cure for only a minority of patients. Although progress has been made in identifying subsets of patients who require chemotherapy alone-as compared with those who require initial chemotherapy followed by allogeneic stem cell transplantation to maximize the chance for cure-clinical and cytogenetic prognosticators are not sufficiently accurate for such a risk-adapted stratification approach. New molecular technologies have allowed for in-depth molecular analyses of AML patients. These studies have revealed novel mutations, epigenetic changes, and/or aberrant expression levels of protein-coding and noncoding genes involved in leukemogenesis. These molecular aberrations are now being increasingly used not only to select risk-adapted treatment strategies, but also to incorporate newer molecularly targeted agents into conventional chemotherapy and/or transplant treatments. The hope is that this approach will lead to a better selection of "personalized" treatments for individual patients at diagnosis, the ability to assess these treatments in real time, and the ability, if necessary, to modify these therapies utilizing molecular endpoints for guidance regarding their antileukemia activity. We review here the state of the art of diagnosis and treatment of AML and provide insights into the emerging novel biomarkers and therapeutic agents that are anticipated to be useful for the implementation of personalized medicine in AML.
    MeSH term(s) DNA-Binding Proteins/genetics ; Epigenesis, Genetic ; Humans ; Immunotherapy ; Leukemia, Myeloid, Acute/genetics ; Leukemia, Myeloid, Acute/therapy ; Mutation ; Nuclear Proteins/genetics ; Prognosis ; Proto-Oncogene Proteins/genetics ; fms-Like Tyrosine Kinase 3/genetics
    Chemical Substances DNA-Binding Proteins ; Nuclear Proteins ; Proto-Oncogene Proteins ; nucleophosmin (117896-08-9) ; TET2 protein, human (EC 1.13.11.-) ; FLT3 protein, human (EC 2.7.10.1) ; fms-Like Tyrosine Kinase 3 (EC 2.7.10.1)
    Language English
    Publishing date 2016-03-22
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 1067950-9
    ISSN 0890-9091
    ISSN 0890-9091
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3168: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 372: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: TET2 deficiency promotes MDS-associated leukemogenesis.

    Huang, Feiteng / Sun, Jie / Chen, Wei / Zhang, Lei / He, Xin / Dong, Haojie / Wu, Yuhui / Wang, Hanying / Li, Zheng / Ball, Brian / Khaled, Samer / Marcucci, Guido / Li, Ling

    Blood cancer journal

    2022  Volume 12, Issue 10, Page(s) 141

    MeSH term(s) DNA-Binding Proteins/genetics ; Dioxygenases ; Humans ; Mutation ; Proto-Oncogene Proteins/genetics
    Chemical Substances DNA-Binding Proteins ; Proto-Oncogene Proteins ; Dioxygenases (EC 1.13.11.-) ; TET2 protein, human (EC 1.13.11.-)
    Language English
    Publishing date 2022-10-04
    Publishing country United States
    Document type Letter ; Research Support, N.I.H., Extramural
    ZDB-ID 2600560-8
    ISSN 2044-5385 ; 2044-5385
    ISSN (online) 2044-5385
    ISSN 2044-5385
    DOI 10.1038/s41408-022-00739-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia.

    Prebet, Thomas / Goldberg, Aaron D / Jurcic, Joseph G / Khaled, Samer / Dail, Monique / Feng, Yuning / Green, Cherie / Li, Chunze / Ma, Connie / Medeiros, Bruno C / Yan, Mark / Grunwald, Michael R

    Leukemia & lymphoma

    2022  Volume 63, Issue 9, Page(s) 2180–2188

    Abstract: This phase 1 b study evaluated the safety, efficacy, and pharmacokinetics of atezolizumab in combination with guadecitabine in patients with relapsed/refractory (R/R) or first-line acute myeloid leukemia (AML). Patients received atezolizumab 840 mg (days ...

    Abstract This phase 1 b study evaluated the safety, efficacy, and pharmacokinetics of atezolizumab in combination with guadecitabine in patients with relapsed/refractory (R/R) or first-line acute myeloid leukemia (AML). Patients received atezolizumab 840 mg (days [D] 8 and 22) and guadecitabine 60 mg/m<sup>2</sup> (D1 and D5) over 28-day cycles. Sixteen patients (median age 73.0 years) enrolled (R/R cohort, n = 11; first-line cohort, n = 5). All patients reported at least 1 AE; 15 patients (93.8%) reported grade ≥ 3 AEs, and 15 patients (93.8%) reported SAEs. Fourteen of the 16 patients (87.5%) died during the trial period due to disease progression (8/14) or AEs (6/14), hence the study was terminated early. One patient (from the R/R AML cohort) achieved a response (CR with incomplete platelet recovery) with a DOR of 27.8 months at study termination. Atezolizumab plus guadecitabine had limited clinical activity in AML and an overall unfavorable benefit-risk profile at the investigated dose levels.
    MeSH term(s) Aged ; Antibodies, Monoclonal, Humanized/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Azacitidine/analogs & derivatives ; Azacitidine/therapeutic use ; Humans ; Leukemia, Myeloid, Acute/diagnosis ; Leukemia, Myeloid, Acute/drug therapy
    Chemical Substances Antibodies, Monoclonal, Humanized ; guadecitabine (2KT4YN1DP7) ; atezolizumab (52CMI0WC3Y) ; Azacitidine (M801H13NRU)
    Language English
    Publishing date 2022-05-01
    Publishing country United States
    Document type Clinical Trial, Phase I ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1042374-6
    ISSN 1029-2403 ; 1042-8194
    ISSN (online) 1029-2403
    ISSN 1042-8194
    DOI 10.1080/10428194.2022.2057484
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2997: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top